Hereditary Transthyretin Amyloidosis (hATTR) Market

Transthyretin Amyloidosis (ATTR) is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body’s organs and tissues.

hATTR is a systemic autosomal dominant disorder characterized by the extracellular deposition of misfolded TTR protein. hATTR cases are divided into two segments which include Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC) cases.

Hereditary Transthyretin Amyloidosis (hATTR) Market Key Facts

In 2017, the total diagnosed prevalent population of hATTR in the 7MM was 11,330.

hATTR is segmented into two groups, i.e., Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC) cases. In 2017, there were 5,241, and 6,089 diagnosed prevalent cases of FAP and FAC, respectively, in the 7MM.

Hereditary Transthyretin Amyloidosis (hATTR) Market

The market size of Hereditary Transthyretin Amyloidosis (hATTR) shall increase during the forecast period (2020–2030), owing to the launch of upcoming therapies.

The Hereditary Transthyretin Amyloidosis (hATTR) market analysis report helps to build the detailed comprehension of the historic, current and forecasted Hereditary Transthyretin Amyloidosis (hATTR) market trends by evaluating the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.

For more details, visit:
https://www.delveinsight.com/report-store/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market